Eton Pharmaceuticals, Inc. (ETON)

Over the past six months, Eton Pharmaceuticals' stock experienced fluctuations, with an all-time high closing price of $22.48 on September 29, 2025. The 52-week high reached $23.00, while the 52-week low was $11.09. As of February 6, 2026, the closing stock price was $14.76. The Q3 2025 earnings transcript was released on November 9, 2025, following a report of a Q3 loss but surpassing revenue estimates. Investor sentiment improved as short interest decreased by 6.25%. Revenue has doubled year-over-year since 2023, with a 108% jump in Q2 2025 revenue. The FDA accepted the NDA for ET-600, with a target action date of February 25, 2026.

Eton Pharmaceuticals has not explicitly reported significant demand seasonality. The company has consistently shown sequential quarter-over-quarter growth in product sales, suggesting that strong seasonal patterns do not appear to be a dominant factor influencing the overall demand for its products.

Eton Pharmaceuticals, Inc. is focused on developing, acquiring, and commercializing prescription drugs, particularly for rare diseases, operating in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. Its product portfolio includes drugs like Biorphen and Alaway Preservative Free, along with commercial rare disease products such as Increlex and Alkindi Sprinkle. Eton also has late-stage product candidates like ET-400 and the ZENEO hydrocortisone autoinjector.

Eton Pharmaceuticals, Inc. is headquartered in Deer Park, Illinois, United States. The company collaborates with development partners across the United States and Europe to build its diversified product portfolio.

Eton Pharmaceuticals has maintained a generally positive brand reputation, ranking higher than 64% of companies in the medical sector. It has a consensus "Hold" rating from analysts, but Zacks Investment Research rates it as a "Sell". Positive events include reporting sequential growth in product sales for 18 consecutive quarters and the successful relaunch of INCRELEX. The company's engagement with the pediatric endocrinology community and the acquisition of U.S. rights to PKU GOLIKE have also contributed positively.

Eton Pharmaceuticals, Inc. has a diverse ownership structure. Institutional investors hold approximately 51.23% of the company's stock, insiders own about 24.57%, and public companies and individual investors account for 24.19%. Major institutional shareholders include Opaleye Management Inc., EcoR1 Capital, LLC, and BlackRock, Inc. David Krempa holds 2.35% of the shares as an individual owner.